Inventiva S.A. (IVA) - Long-Term Debt to Capital

Inventiva S.A. (IVA) focuses on developing innovative small molecules to combat fibrosis, attracting major partners for global expansion. While its key product is currently completing final trials, significant protocol costs are constraining profit growth until sales commence. The French biotech firm aims to capture a massive segment of hepatology with its unique drug. This chart reflects the price action of Inventiva S.A. (IVA) at 0.88.

This ratio determines the share of long-term liabilities within the equity structure, reflecting the degree of financial autonomy and the risk of corporate over-leverage. By analyzing the history of long-term debt leverage, an investor assesses the ability of Inventiva S.A. (IVA) to sustain the cost of medical protocols until the final drug tests are completed, at which point fixed costs will be replaced by commercial revenue.